Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

May 9, 2025

Study Completion Date

September 30, 2025

Conditions
Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Interventions
DRUG

D-4517.2

D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)

Trial Locations (16)

16507

Erie Retina Research, Eire

20176

Virginia Retina Center, Leesburg

21740

Cumberland Valley Retina Consultants, Hagerstown

26505

West Virginia University Eye Institute, Morgantown

46290

Midwest Eye Institute - North, Indianapolis

60439

University Retina - Lemont, Lemont

62794

Springield Clinic, Springfield

63128

The Retina Institute - Clayton Office, St Louis

76012

Texas Retina Associates - Arlington, Arlington

76087

Strategic Clinical Research Group, Willow Park

78240

Medical Center Ophthalmology Associates - Northwest, San Antonio

Retinal Consultants of San Antonio, San Antonio

78705

Austin Retina Associates, Austin

90026

Macro Trials, Los Angeles

02114

Ophthalmic Consultants of Boston, Boston

07003

Envision Ocular, LLC, Bloomfield

Sponsors
All Listed Sponsors
lead

Ashvattha Therapeutics, Inc.

INDUSTRY

NCT05387837 - Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME | Biotech Hunter | Biotech Hunter